Interpace Biosciences amends 8-K to disclose adoption of 2026 equity incentive, employee stock purchase plans

Reuters2026/08/26 14:46

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Interpace Biosciences filed an amended Form 8-K to correct its Aug. 20, 2026 report by adding disclosure of new benefit plans.
The amendment confirms stockholder adoption of a 2026 Equity Incentive Plan, replacing the 2019 Equity Incentive Plan.
It also confirms adoption of a 2026 Employee Stock Purchase Plan, replacing the 2019 Employee Stock Purchase Plan.
No further equity grants will be made under the 2019 plan. No further purchases will be allowed under the 2019 ESPP.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Interpace Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-040182), on August 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Interpace Biosciences amends 8-K to disclose adoption of 2026 equity incentive, employee stock purchase plans

You may also like

Crypto prices